References
- . Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917–1928
- . Fanapt (iloperidone) tablets [package insert]. Revised August 2010. Rockville, MD: Vanda Pharmaceuticals. http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf. Accessed November 10, 2010
- . Saphris (asenapine) sublingual tablets [package insert]. Revised September 2010. Whitehouse Station, NJ: Merck and Co, Inc. http://www.spfiles.com/pisaphrisv1.pdf. Accessed November 10, 2010
- . Latuda (lurasidone HCl) tablets [package insert]. Sunovion Pharmaceuticals Inc. Marlborough, MA. http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed November 10, 2010
- . Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009;63(8):1237–1248
- . Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707–718
- . Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551–1564
- . Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762–1784
- . Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2)189–210
- . Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 suppl 1):S20–S28
- . Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 suppl 1):S4–S11
- . Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 suppl 1):S12–S19
- . Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–1500
- . United States Food and Drug Administration. Saphris (asenapine) sublingual tablets. Briefing Book. July 30, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf. Accessed December 16, 2010
- . Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–115
- . Schering-Plough Research Institute. SAPHRIS (asenapine) sublingual tablets. Briefing document (background package). July 30, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf. Accessed December 16, 2010
- . McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2): 27–38
- . McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–686
- . Schering-Plough. To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012) (Completed) (P05770). Study results. June 17, 2010. http://clinicaltrials.gov/ct2/show/results/NCT00150176. Accessed December 16, 2010
- . Calabrese J, Stet L, Kotari H, . PW01–28 – Asenapine as adjunctive treatment for bipolar mania: a placebo-controlled 12-week study and 40-week extension. Abstract. Eur Psychiatry. 2010;2 ( suppl 1):1447
- . Nakamura M, Ogasa M, Guarino J, . Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–836
- . US Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) tablets. December 3, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000TOC.cfm. Accessed December 16, 2010
- . Citrome L. Using ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26(8):739–748
- . Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;(3):229–237
- . Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137–177
- . Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2(4):427–443
- . Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41
- . Leucht S, Komossa K, Rummel-Kluge C, . A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163
- . Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–447